---
company: NEOGENOMICS INC
ticker: NEO
form: 8-K
filed: 2026-10-28
accepted: 2026-10-28T20:06:56+00:00
accession: 0001077183-26-000078
source: https://www.sec.gov/Archives/edgar/data/1077183/000107718326000078/
---

# Neogenomics (NEO) Q3 2026 earnings

## Header

- Company: Neogenomics Inc
- Reported: 2026-10-28 16:06 AMC ET
- Source: 8-K only — accession 0001077183-26-000078, Item 2.02 + Exhibit 99.1
- Verdict: Revenue and adjusted EBITDA grew double-digits, and the company raised full-year revenue guidance.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---|---|
| Revenue | $209.3M | +11.4% | — | Income Statement (Three Months Ended September 30, – 2026) |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---|---|
| Clinical services | 13% growth | +13% | 100% (Total) | Clinical volume +2%, average revenue per test +11% to $530 |
| NGS | 29% growth | +29% | Included in Clinical services | NGS test volume grew 17% |

## Margins and costs

- Gross margin: 46.2% (prior 42.8%, change +3.4 pp)
- Operating expenses: $105.0M (decrease of $3M, or 3%)
- One-offs in the quarter: Impairment charges (Q3 2025: $7.1M); Gain on extinguishment of debt (Q3 2025: $11.2M); IP litigation costs (Q3 2025: $3.6M)
- Effective tax rate: Not stated
- Non-GAAP bridge: Adds back interest income/expense, tax benefit/expense, depreciation, amortization, leadership transition costs, acquisition and integration expenses, stock-based compensation, gain on extinguishment of debt, impairment charges, IP litigation costs, and contingency for regulatory matter

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---|---|
| Cash and cash equivalents | $139.3M | $159.6M | — | -$20.3M |
| Accounts receivable, net | $213.4M | $159.2M | — | +$54.2M |
| Weighted average common shares outstanding (diluted) | 128,587 | 128,415 | — | +172 |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---|---:|---|
| Consolidated revenue | $807M - $809M | $802M - $806M | +$5M - $3M |
| Adjusted EBITDA | Approximately $60M | $56M - $58M | +$2M - $4M |
| Adjusted diluted EPS | $0.21 - $0.22 | — | — |

## What drove it

- Revenue story: Total revenue increased 11% YoY to $209.3M; Clinical services revenue grew 13% with NGS revenue growing 29% and test volume growing 17%.
- EPS story: Net loss improved to $7.5M from $27.1M YoY, driven by revenue growth, margin expansion, and lower operating expenses.
- One-off check: Impairment charges $0 (Q3 2026) vs $7.1M (Q3 2025); Gain on extinguishment of debt $0 (Q3 2026) vs $11.2M (Q3 2025); IP litigation costs $0.04M (Q3 2026) vs $3.6M (Q3 2025).

## The good

- Adjusted EBITDA increased 53% YoY to $19M
- Adjusted Gross Profit Margin increased 310 bps YoY to 49%
- Operating expenses decreased 3% YoY to $105M

## The bad

- Net loss of $7.5M remains negative
- Cash and cash equivalents decreased $20.3M YoY

## The ugly

- none

## Open questions

- The filing does not disclose the specific revenue mix by segment (e.g., Clinical vs. Research) or the exact dollar amount of NGS revenue.
- The filing does not disclose the specific impact of the leadership transition costs on the adjusted EBITDA or net income.

## Full release

### Earnings: NEO — filed 2026-10-28

Neogenomics Inc (NEO) · Form 8-K, Item 2.02 · Filed 2026-10-28 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1077183/000107718326000078/)

NeoGenomics Reports Third Quarter 2026 Results

Total revenue increased 11% YoY to $209 million

Clinical services revenue grew 13%, with NGS revenue growth of 29%

Company raises full-year 2026 revenue and adjusted EBITDA guidance

Fort Myers, Florida (October 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the

“

Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third-quarter results for the period ended September 30, 2026.

“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%. As our business continues its shift to higher-value, high-margin testing modalities, we see further opportunity to invest into our commercial teams, community channel strength, and product pipeline. At the same time, we expect to reduce complexity across our business through operational excellence initiatives designed to deliver accelerating growth and disciplined margin expansion over the long-term.”

Third-Quarter Results

Consolidated revenue for the third quarter of 2026 was $209 million, an increase of 11% over the same period in 2025. Clinical volume increased by 2%, while average revenue per clinical test increased by 11% to $530.

Consolidated gross profit for the third quarter of 2026 was $97 million, an increase of 20% compared to the third quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 46%. Adjusted Gross Profit Margin

(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 49%, an increase of 310 bps versus the same period in 2025.

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

|

2

Operating expenses for the third quarter of 2026 were $105 million, a decrease of $3 million, or 3%, compared to the third quarter of 2025.

Net loss for the quarter was $8 million compared to net loss of $27 million for the third quarter of 2025.

Adjusted EBITDA

(1) for the third quarter of 2026 increased by 53% to $19 million, compared to $12 million in the third quarter of 2025. Adjusted Net Income

(1) was $11 million compared to Adjusted Net Income

(1) of $4 million in the third quarter of 2025.

Cash and cash equivalents totaled $139 million at quarter end.

(1)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.

2026 Financial Guidance

The Company is revising its full-year 2026 guidance, as shown below (in millions).

Conference Call

The Company has scheduled a webcast and conference call to discuss its third quarter 2026 results on Wednesday,

October 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 489662. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).

Forward Looking Statements

This press release, and the conference call and webcast referenced above, contain forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “target,” “enable,” “intend,” “potential” and other words of similar meaning, although not all forward-looking statements include these words.

These forward-looking statements include, among others, statements regarding the Company’s full-year 2026 financial guidance and the assumptions underlying that guidance; the strategic execution of the Company’s leadership team and the Company’s plans with respect to executive leadership succession, including the anticipated timing and effects thereof; the

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

|

2... (truncated)l position; the Company’s future operating and financial performance; the Company’s growth potential and expected growth drivers, including with respect to next-generation sequencing (NGS) and molecular residual disease (MRD) testing; projected costs and capital expenditures; the Company’s prospects and plans; the Company’s belief in the durability of its broad-based testing solutions portfolio; the Company’s expectations regarding its ability for realizing efficiencies from operational excellence initiatives; estimates of market size and position; and the objectives of management.

Each forward-looking statement contained in this press release, or made during the related conference call and webcast, is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities; to achieve the revenue, net loss and Adjusted EBITDA results contemplated by its guidance; to realize anticipated efficiencies, cost savings and margin improvement from its operational initiatives, including in light of compensation, benefits and supplies cost inflation; to enter new markets and increase market share in both current and new markets; to continue gaining new customers; to develop, validate and commercialize new types of tests; to obtain and maintain coverage and reimbursement for its tests; to bill and collect for its services on a timely basis and to accurately estimate amounts expected to be collected, including implicit price concessions; to assemble and maintain an effective executive team and retain key personnel, including in connection with its announced leadership succession; to integrate acquired businesses and realize their anticipated benefits; to manage the effects of seasonality and changes in payer mix; and to otherwise implement its business plans. Applicable risks and uncertainties also include the potential impact of evolving regulatory requirements related to laboratory developed tests; the impact of tariffs and trade policy uncertainty on the Company’s supply chain and costs; potential reimbursement or coverage changes by government and commercial payers; the Company’s compliance with, and the cost of complying with, healthcare laws and regulations; risks relating to potential dilution to the Company’s stockholders upon conversion of its outstanding convertible senior notes; the outcome of pending legal proceedings; and the risks identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 17, 2026, and in the Company’s other filings with the SEC.

The Company’s full-year 2026 guidance is based on management’s current expectations and assumptions as of the date of this press release. Actual results may differ materially.

The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or made during the related conference call and webcast. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and forward-looking statements made during the related conference call and webcast speak only as of the date of that call (unless another date is indicated), and the Company undertakes no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Any replay or archived version of the conference call or webcast is provided for convenience only, and the statements made therein are not updated or reaffirmed as of any later date.

Investor Contact

InvestorRelations@neogenomics.com

Media Contact

Andrea Sampson asampson@sampsonprgroup.com

NeoGenomics, Inc. | 9490 NeoGenomics Way, Fort Myers, FL 33912

Page

|

3

#### Financial statements

##### Income Statement (Previous FY 2026 Guidance — The Company is revising its full-year 2026 guidance, as shown below (in millions).)

| | FY 2025 – Actual | Previous FY 2026 Guidance – Low | Previous FY 2026 Guidance – High | Updated FY 2026 Guidance – Low | Updated FY 2026 Guidance – High | YOY % Change from FY 2025 – Low | YOY % Change from FY 2025 – High |
|---|---:|---:|---:|---:|---:|---:|---:|
| Consolidated revenue | 727 | 802 | 806 | 807 | 809 | 11.0% | 11.0% |
| Net loss | -108 | -42 | -34 | -32 | -30 | 70.0% | 72.0% |
| Adjusted EBITDA | 43 | 56 | 58 | Approximately $60 |  | Approximately 38% |  |

##### Income Statement (Three Months Ended September 30, — (unaudited))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| NET REVENUE | 209,254 | 187,797 | 597,582 | 537,162 |
| COST OF REVENUE | 112,666 | 107,351 | 328,252 | 306,212 |
| GROSS PROFIT | 96,588 | 80,446 | 269,330 | 230,950 |
| Operating expenses: | General and administrative | 67,073 | 69,874 | 196,427 | 209,828 |
| Operating expenses: | Research and development | 9,855 | 8,694 | 30,150 | 27,898 |
| Operating expenses: | Sales and marketing | 27,601 | 21,806 | 78,706 | 68,564 |
| Operating expenses: | Impairment charges |  | 7,086 |  | 27,127 |
| Operating expenses: | Total operating expenses | 104,529 | 107,460 | 305,283 | 333,417 |
| Operating expenses: | LOSS FROM OPERATIONS | -7,941 | -27,014 | -35,953 | -102,467 |
| Operating expenses: | Interest income | 1,196 | 1,563 | 3,683 | 7,547 |
| Operating expenses: | Interest expense | -1,267 | -603 | -2,646 | -3,154 |
| Operating expenses: | Other (expense) income, net | -9 | -335 | -38 | 212 |
| Operating expenses: | Gain on extinguishment of debt |  |  | 11,181 |  |
| Operating expenses: | Loss before taxes | -8,021 | -26,389 | -23,773 | -97,862 |
| Operating expenses: | Income tax benefit (expense) | 475 | -740 | 1,359 | -282 |
| Operating expenses: | NET LOSS | -7,546 | -27,129 | -22,414 | -98,144 |
| NET LOSS PER SHARE | Basic | -0.06 | -0.21 | -0.17 | -0.77 |
| NET LOSS PER SHARE | Diluted | -0.06 | -0.21 | -0.17 | -0.77 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | Basic | 128,587 | 128,415 | 129,125 | 127,917 |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | Diluted | 128,587 | 128,415 | 129,125 | 127,917 |

##### Income Statement (Three Months Ended September 30, — (unaudited))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss (GAAP) | -7,546 | -27,129 | -22,414 | -98,144 |
| Adjustments to net loss: | Interest income | -1,196 | -1,563 | -3,683 | -7,547 |
| Adjustments to net loss: | Interest expense | 1,267 | 603 | 2,646 | 3,154 |
| Adjustments to net loss: | Income tax (benefit) expense | -475 | 740 | -1,359 | 282 |
| Adjustments to net loss: | Depreciation | 8,555 | 8,803 | 25,912 | 27,309 |
| Adjustments to net loss: | Amortization | 8,023 | 7,634 | 23,630 | 24,120 |
| Adjustments to net loss: | EBITDA (non-GAAP) | 8,628 | -10,912 | 24,732 | -50,826 |
| Further adjustments to EBITDA: | Leadership transition costs(1) | 1,073 | 319 | 1,636 | 3,149 |
| Further adjustments to EBITDA: | Acquisition and integration related expenses(2) |  | 1,800 | 806 | 6,176 |
| Further adjustments to EBITDA: | Stock-based compensation expense | 8,837 | 10,305 | 26,689 | 33,274 |
| Further adjustments to EBITDA: | Gain on extinguishment of debt |  |  | -11,181 |  |
| Further adjustments to EBITDA: | Impairment charges(3) |  | 7,086 |  | 27,127 |
| Further adjustments to EBITDA: | IP litigation costs(4) | 42 | 3,634 | 207 | 11,077 |
| Further adjustments to EBITDA: | Adjustment to contingency for regulatory matter |  |  | -1,155 |  |
| Further adjustments to EBITDA: | Other significant expenses, net(5) | 89 |  | 406 |  |
| Further adjustments to EBITDA: | Adjusted EBITDA (non-GAAP) | 18,669 | 12,232 | 42,140 | 29,977 |

##### Income Statement (Three Months Ended September 30, — (unaudited))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Three Months Ended September 30, – 2025 | Three Months Ended September 30, – % Change | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2025 | Nine Months Ended September 30, – % Change |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Consolidated: | Total revenue (GAAP) |  | 209,254 |  | 187,797 | 11.4% |  | 597,582 |  | 537,162 | 11.2% |
| Consolidated: | Cost of revenue (GAAP) |  | 112,666 |  | 107,351 | 5.0% |  | 328,252 |  | 306,212 | 7.2% |
| Consolidated: | Adjustments to cost of revenue(1) | -5,029 |  | -4,950 |  |  | -15,001 |  | -15,389 |  |  |
| Consolidated: | Adjusted cost of revenue (non-GAAP) |  | 107,637 |  | 102,401 | 5.1% |  | 313,251 |  | 290,823 | 7.7% |
| Consolidated: | Gross profit (GAAP) |  | 96,588 |  | 80,446 | 20.1% |  | 269,330 |  | 230,950 | 16.6% |
| Consolidated: | Adjusted gross profit (non-GAAP ) |  | 101,617 |  | 85,396 | 19.0% |  | 284,331 |  | 246,339 | 15.4% |
| Consolidated: | Gross profit margin (GAAP) | 46.2 | % | 42.8 | % |  | 45.1 | % | 43 | % |  |
| Consolidated: | Adjusted gross profit margin (non-GAAP) | 48.6 | % | 45.5 | % |  | 47.6 | % | 45.9 | % |  |

##### Income Statement (Three Months Ended September 30, — (unaudited))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net loss (GAAP) | -7,546 | -27,129 | -22,414 | -98,144 |
| Adjustments to net loss net of tax: | Amortization | 8,023 | 7,634 | 23,630 | 24,120 |
| Adjustments to net loss net of tax: | Leadership transition costs(1) | 1,073 | 319 | 1,636 | 3,149 |
| Adjustments to net loss net of tax: | Acquisition and integration related expenses(2) |  | 1,800 | 806 | 6,176 |
| Adjustments to net loss net of tax: | Stock-based compensation expense | 8,837 | 10,305 | 26,689 | 33,274 |
| Adjustments to net loss net of tax: | Gain on extinguishment of debt |  |  | -11,181 |  |

##### Income Statement (Year Ended December 31, 2026)

| | Year Ended December 31, 2026 – Low Range | Year Ended December 31, 2026 – High Range |
|---|---:|---:|
| Net loss (GAAP) | -32,000 | -30,000 |
| Amortization | 32,000 | 32,000 |
| Stock-based compensation expenses | 36,000 | 35,000 |
| Other one-time expenses | -9,000 | -9,000 |
| Adjusted net income (non-GAAP) | 27,000 | 28,000 |
| Interest and taxes | -1,000 | -2,000 |
| Depreciation | 34,000 | 34,000 |
| Adjusted EBITDA (non-GAAP) | 60,000 | 60,000 |
| Net loss per diluted share (GAAP) | -0.25 | -0.23 |
| Adjustments to net loss per diluted share: | Amortization | 0.25 | 0.25 |
| Adjustments to net loss per diluted share: | Stock-based compensation expenses | 0.28 | 0.27 |
| Adjustments to net loss per diluted share: | Other one-time expenses | -0.07 | -0.07 |
| Adjustments to net loss per diluted share: | Adjusted diluted EPS (non-GAAP) | 0.21 | 0.22 |
| Weighted average assumed shares outstanding in 2026: | Diluted shares (GAAP) | 129,500 | 129,500 |
| Weighted average assumed shares outstanding in 2026: | Adjusted diluted shares outstanding (non-GAAP) | 129,500 | 129,500 |

##### Balance Sheet (December 31, 2025 — (in thousands))

| | September 30, 2026 (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 139,281 | 159,618 |
| Current assets | Accounts receivable, net | 213,410 | 159,242 |
| Current assets | Inventories | 25,500 | 28,566 |
| Current assets | Prepaid assets | 22,774 | 21,443 |
| Current assets | Other current assets | 9,118 | 7,417 |
| Current assets | Total current assets | 410,083 | 376,286 |
| Current assets | Property and equipment, net | 85,944 | 84,834 |
| Current assets | Operating lease right-of-use assets | 77,978 | 78,444 |
| Current assets | Financing lease right-of-use assets | 6,291 | 54 |
| Current assets | Intangible assets, net | 263,628 | 286,528 |
| Current assets | Goodwill | 523,995 | 524,344 |
| Current assets | Other assets | 8,998 | 9,340 |
| Current assets | Total non-current assets | 966,834 | 983,544 |
| Current assets | Total assets | 1,376,917 | 1,359,830 |
| Current liabilities | Accounts payable and other current liabilities | 110,174 | 83,496 |
| Current liabilities | Current portion of operating lease liabilities | 4,295 | 4,776 |
| Current liabilities | Current portion of finance lease liabilities | 1,704 | 28 |
| Current liabilities | Total current liabilities | 116,173 | 88,300 |
| Long-term liabilities | Operating lease liabilities | 64,303 | 62,822 |
| Long-term liabilities | Finance lease liabilities | 4,151 | 27 |
| Long-term liabilities | Convertible senior notes, net | 374,688 | 341,858 |
| Long-term liabilities | Deferred income tax liabilities, net | 16,097 | 18,219 |
| Long-term liabilities | Other long-term liabilities | 867 | 12,042 |
| Long-term liabilities | Total long-term liabilities | 460,106 | 434,968 |
| Long-term liabilities | Total liabilities | 576,279 | 523,268 |
| Stockholders’ equity | Total stockholders' equity | 800,638 | 836,562 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 1,376,917 | 1,359,830 |

##### Cash Flow (Nine Months Ended September 30, — (unaudited))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net loss | -22,414 | -98,144 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Depreciation | 25,912 | 27,309 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Amortization of intangibles | 22,900 | 24,120 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Stock-based compensation | 26,689 | 33,274 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Non-cash operating lease expense | 4,764 | 5,039 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Non-cash finance lease amortization | 684 |  |
